Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
John Ling
Institution:
Gilead Sciences (United States)
Observed institution:
Gilead Sciences (United States)
OpenAlex ID:
A5122812613
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
2026
·
Linda-Gail Bekker
, Dhayendre Moodley
, et al.
·
The Lancet HIV
·
1
A Phase 1 Study to Evaluate the Potential Drug–Drug Interaction Between Islatravir and Lenacapavir
2026
·
Haeyoung Zhang
, Steve West
, et al.
·
The Journal of Clinical Pharmacology
PDF
Evaluation of Relative Bioavailability and Food Effect of a Fixed‐Dose Combination Tablet of Islatravir and Lenacapavir
2026
·
Jing Niu
, Haeyoung Zhang
, et al.
·
The Journal of Clinical Pharmacology
P-359. Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir
2026
·
Jing Niu
, Haeyoung Zhang
, et al.
·
Open Forum Infectious Diseases
PDF
Show more works
View as search
Works count:
4
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type
